Robert Meier
Robert M. Meier, M.D.

Robert M. Meier, M.D.

Robert M. Meier, M.D.
Specialty

Oncology - Radiation

Clinical Interests / Special Procedures Performed

CyberKnife, Gamma Knife

  • Accepting Children: No
  • Accepting New Patients: Yes
  • Accepting Medicare: Yes
  • Accepting Medicaid/DSHS: Yes
Payment Methods Accepted:

Medicare, Medicaid/DSHS, Bill Insurance, VISA, Master Card, Cash, Check, American Express, Discover Card, Money Order

Insurance Accepted:

Contact this office for accepted insurance plans.

Additional Information:

Internal Medicine Internship: St. Mary Medical Center: Long Beach, California

Academic Appointment: Stanford University Department of Radiation Oncology, Adjunct Clinical Assistant Professor (1990-2005)

Philosophy of Care

Physicians have the great privilege of being entrusted to guide patients on a path to better health. Oncologists have the difficult task of rendering therapies which can add years of life, but may take from the quality of those years. My desire to add quality and years to my patients’ lives is what drives me to do cancer research.

Personal Interests

In my free time I enjoy running, traveling, skiing and spending time with my son.

Medical School

University of California Los Angeles

Residency

University of California Los Angeles

Board Certifications

American Board of Radiology

Additional Information:

Internal Medicine Internship: St. Mary Medical Center: Long Beach, California

Academic Appointment: Stanford University Department of Radiation Oncology, Adjunct Clinical Assistant Professor (1990-2005)

RESEARCH GRANTS:

National Principal Investigator, CyberKnife Radiosurgery for Organ-Confined Prostate
Cancer: Homogenous Dose Distribution. An on-going multi-institutional study; ClinicalTrials.gov Identifier: NCT00643994

PUBLICATIONS:

Meier R, Beckman A et al. Stereotactic Radiotherapy for Organ-confined Prostate Cancer:
First Author Early Toxicity and Quality of Life Outcomes from a Multi-institutional Trial. Intern J Radiat Oncol Biol Phys 78(3): S57, 2010

Meier R, Sanda M, Kaplan I. Robotic Radiosurgery for Organ-confined Prostate Cancer: Early Toxicity Outcomes from a Multi-institutional Trial. J Urology 183(4): e785, 2010

Meier R, Cotrutz C. MRI-planned Stereotactic Body Radiotherapy for Organ-confined Prostate Cancer: Feasibility & Early Results. Intern J Radiat Oncol Biol Phys 75(3):S334, 2009

Meier R, Mehta V, Vermeulen S, Young R. Dose-response and dose-complication
relationships in stereotactic radiosurgery for trigeminal neuralgia. Intern J Radiat Oncol Biol Phys. 60(1): S547, 2004

Meier R, Hatton J, Mehta V. Forward-planning breast IMRT: early clinical experience. Intern J Radiat Oncol Biol Phys. 57(2): S368, 2003

Meier R, Brawer M. Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. Reviews in Urology. 4(3); 141-46, 2002

Meier R, Mark R, St. Royal L, Tran L, Colburn G, Parker R. Postoperative radiotherapy
following radical prostatectomy for prostate carcinoma. Cancer. 1992; 70:1960-1966.

Posnsky L, Fuller D, Meier R, Ma C (Editors): Treating Prostate Cancer and Related Genitourinary Applications. New York: Springer-Verlag, 2012.

Vermeulen S, Cotrutz C, Morris A, Meier R, Buchanan C, Dawson P, Porter B. Accelerated partial breast irradiation: using the CyberKnife as the radiation delivery platform in the treatment of early breast cancer. Front. Oncol. 1:43, 2001.

Young RF, Li F, Vermeulen S, Meier R, Gamma Knife thalamotomy for treatment of essential tremor: long-term results. J Neurosurg. 2009 Nov 6.

Sylvester J, Blasko J, Grimm P, Meier R, Malmgren J. Ten-year biochemical relapse-free
survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Intern J Radiat Oncol Biol Phys. 57(4): 944-52, 2003

Grimm P, Blasko J, Sylvester J, Meier R, Cavanagh W. Ten-year biochemical (prostate- specific antigen) control of prostate cancer with 125-I brachytherapy. Intern J Radiat Oncol
Biol Phys. 51(1): 31-40, 2001

Sylvester J, Grimm P, Blasko J, Meier R, Spiegel J, Heaney C, Cavanagh W. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns or urologists and radiation oncologists in the United States. Urology. 58(2 suppl 1):65-70, 2001.

Grimm P, Blasko J, Sylvester J, Cavanagh W, Meier R. Ten year biochemical outcomes following 125-iodine monotherapy for early stage prostate cancer. Intern J Radiat Oncol Biol Phys. 48(3): 146-147, 2000.

Sylvester J, Blasko J, Grimm P, Meier R, Cavanagh W. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate brachytherapy in early-stage prostate cancer: a matched subset analysis. Molecular Urology. 4(3):155-59, 2000

Vermeulen S, Young R, Li F, Meier R, Raisis J, Klein S, Kohler E. Comparison of single fraction radiosurgery tumor control and toxicity in the treatment of basal and nonbasal meningiomas. Stereotact & Funct Neurosurg. 72(suppl. 1): 60-66, 1999.

Sylvester J, Blasko J, Grimm P, Meier R, Colburn G, Goy B, Cavanagh W. Neoadjuvant
androgen ablation combined with exernal beam radiotherapy and brachytherapy in early
stage prostate cancer. Molecular Urology. 1999; 3:231-238.

Tran L, Mark R, Meier R, Calcaterra T, Parker R. Sarcomas of the head and neck:
Prognostic factors and treatment strategies. Cancer. 1992; 70:169-177.

PRESENTATIONS:

Stereotactic Radiotherapy for Organ-confined Prostate Cancer: Early Toxicity and Quality of
National Meetings Life Outcomes from a Multi-institutional Trial. 52nd Annual Meeting of the American Society for Therapeutic Radiation Oncology, November 2010, San Diego, California

Radiosurgery for Organ-confined Prostate Cancer: Early Toxicity Outcomes from a Multi-institutional Trial. 105th Annual Meeting of the American Urologic Association, June 2, 2010, San Francisco, California

MRI-Planned Stereotactic Body Radiotherapy for Organ-Confined Prostate Cancer: Feasibility
and Early Results. 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology, November 2009, Chicago, Illinois

Stereotactic body radiotherapy for organ-confined prostate cancer: Feasibility and early results. Presented at the 91st Annual Meeting of the American Radium Society, April 2009.

Dose-response and dose-complication relationships in stereotactic radiosurgery for trigeminal
neuralgia. Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiation Oncology, October, 2004, Atlanta, Georgia

Forward-planning breast IMRT: early clinical experience. Presented at 45th Annual Meeting of the American Society for Therapeutic Radiation Oncology, October 2003, Salt Lake City Utah

Acute genitourinary complications of permanent interstitial prostate brachytherapy,
National Meetings presented at the Annual Meeting of the Radiologic Society of North America, November 1999.

Postoperative radiation therapy for pathologic stage C prostate carcinoma, presented at the
71st Annual Meeting of the American Radium Society, April 1989.

ADDITIONAL EXPERIENCE:

CyberKnife Radiotherapy, Swedish Radiosurgery Center (Swedish Hospital)

Stereotactic radiosurgery using the Gamma Knife, for intracranial neoplasias and functional
Disorders, Swedish Radiosurgery Center (Swedish Hospital)

Permanent transperineal prostate brachytherapy (Seattle Prostate Institute, Swedish Cancer Institute, and Southwest Tumor Institute)

Temporary transperineal prostate brachytherapy (HDR, Swedish Hospital; LDR training at
California Endocurietherapy and Long Beach Memorial Medical Center)

Interstitial and intracavitary brachytherapy for gynecologic and head and neck malignancies, Stanford Hospital and Kaiser Santa Clara Hospital

Intravascular coronary brachytherapy to prevent restenosis (Swedish Hospital)

Intraoperative radiotherapy (orthovoltage unit, Stanford University Hospital)

Externally applied hyperthermia (Palo Alto Medical Foundation)

Quality of Life Following CyberKnife Treatment for Prostate Cancer

The Swedish Radiosurgery Center is the lead site in a national multi-institutional study evaluating CyberKnife for treating men with intermediate-risk prostate cancer (clinical stage 2). As the principal investigator of this study, I reported on the quality of life outcomes at the annual meeting of American Society of Radiation Oncology.

We now know that in low-risk prostate cancer patients (stage 1), active surveillance is a safe option. But men with intermediate-risk cancer have a significant risk of dying of their disease, so intervention is necessary. Conventional treatments (surgery, radioactive seed implants and external beam radiotherapy) can adversely affect patients’ quality of life.  We sought to determine if the unprecedented accuracy of CyberKnife treatment would translate into improvement in these patients’ quality of life.

We treated ..

Noninvasive Prostate Cancer Treatment Data is Maturing & Promising

Many of my patients are men seeking prostate cancer treatment they can undergo while continuing work and maintaining active lifestyles. Equally important is the cancer-free survival rate and long-term side effect profile. For over seven years we have been treating men with organ-confined prostate cancer using the CyberKnife® stereotactic radiosurgery system. This sophisticated radiation delivery system uses a robotic arm to deliver precise treatment doses to the prostate in only 5 sessions so the men can keep up their normal routine while combatting their disease.

The data supporting this treatment option continues to grow and a recent study following men for 6 years reports patients had excellent biochemical control rates (based on...

You've been diagnosed with prostate cancer - now what?

Almost daily there are new recommendations for how to treat prostate cancer and an equal number of controversies surrounding the recommendations. What is a man to do when faced with the words, “you have prostate cancer”?

The good news is that there are many proven options to consider; but how do you choose the best one for you? The decision can be daunting and the controversies swirling in the news only increase the confusion when wading through the information. You may be considering:

  • Active surveillance (watchful waiting) is an option for those who want to closely monitor their cancer over short intervals. Intervention is considered if the cancer grows quickly, PSA scores increase or other situations arise warranting a more aggressive treatment plan.

  • Surgical options are available and with the advances in robotic technologies, the procedure is less invasive than in the past, recovery times are reduced and fewer side effects are reported. 

  • Radiation options are also available and treat the cancer either with external radiation beams or implanted radioactive seeds.

    • CyberKnife Radiosurgery uses robotic technology to track the prostate in real time and delivers high doses of radiation with pinpoint accuracy. This is an outpatient procedure where the patient comes to the center for five, one hour sessions over the course of one week. Long term side effects are rare and cancer free survival rates are excellent. (You can learn more here.)

    • Seed Implantation is another method of delivering radiation to treat prostate cancer. With this option, the radiation is delivered internally via tiny radioactive seeds which are implanted into the prostate. This too is an outpatient procedure and long term results are excellent and side effects are few. 

As a radiation oncologist specializing in treating prostate cancer...

Results 1-3 of 3
  • 1

Offices

Radiosurgery Center
550 17th Ave.
Suite A10
Seattle, WA 98122
Phone: 206-320-7130
Fax: 206-320-7137
Office Hours: Monday-Friday. 8 a.m.-4:30 p.m
Map & Directions

Physicians: Is this your profile? Click here for info